55 Corporate Drive
164 articles with Sanofi
Kymera Therapeutics And Sanofi Enter Into Strategic Partnership To Advance Novel Protein Degrader Therapies To Patients
Kymera to receive $150 million upfront with more than $2 billion in potential milestones plus royalty payments
SARCLISA™ (isatuximab for injection) now available in Canada for patients with relapsed and refractory multiple myeloma
Sanofi Canada is pleased to announce that Health Canada has approved SARCLISA™ in combination with pomalidomide and dexamethasone for the treatment of adults with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.2
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 6, 2020.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Phase 3 trial of Kevzara ® (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints when Kevzara was added to best supportive care compared to best supportive car
Thrombosis Research Institute (TRI) Announce ETHIC Trial to Evaluate the Potential Benefits of Early Administration of LMWH in Patients with COVID-19
Participants will be randomised to receive the low molecular weight Heparin enoxaparin or current standard of care for up to 3 weeks from the time of diagnosis
Sanofi and Translate Bio Expand Collaboration to Develop mRNA Vaccines Across All Infectious Disease Areas
The two companies will build upon their existing collaboration to pursue novel mRNA vaccines aimed at broadly addressing current and future infectious diseases
Principia Announces First Patient Enrolled in Sanofi’s Phase 3 Trial of SAR442168 in Relapsing Multiple SclerosisDosing of Patient Will Trigger $50 Million Milestone Payment
Principia Biopharma Inc., a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, announced that the first patient has been enrolled in its partner Sanofi’s Phase 3 clinical trial of SAR442168 in patients with relapsing multiple sclerosis.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 17, 2020.
Preclinical data for Sanofi's investigational compounds in breast, lung, multiple myeloma and other cancers will be featured at the American Academy of Cancer Research Virtual Annual Meeting II on June 22-24.
Sobi and Sanofi Donate up to 500 Million Additional IUs of Clotting Factor to WFH Humanitarian Aid Program
Additional donation of factor therapy fulfils 2014 pledge to donate up to an unprecedented 1 billion IUs for humanitarian use
Sanofi and Sobi donate up to 500 million additional IUs of clotting factor to WFH Humanitarian Aid Program
Additional donation of factor therapy fulfills 2014 pledge to donate up to an unprecedented 1 billion IUs for humanitarian use
Dupixent meets early efficacy threshold for continuation in ongoing Phase 3 trial of patients with COPD; second confirmatory trial will commence in third quarter of 2020
KN026 is an anti-HER2 bispecific antibody which can simultaneously bind two non-overlapping epitopes of HER2 and lead to a dual HER2 signal blockade, presumedly causing HER2 to aggregate on the cell surface and endocytose.
Regeneron Announces Secondary Offering of its Common Stock Held by Sanofi and $5 Billion Stock Repurchase
Regeneron Pharmaceuticals, Inc. announced the commencement of an underwritten public secondary offering of its common stock through which Sanofi intends to exit its investment in Regeneron shares.
New data for Sarclisa® (isatuximab-irfc) and Jevtana® (cabazitaxel) in difficult-to-treat cancers reinforce breadth and depth of portfolio
Libtayo® (cemiplimab) Shows Clinically-Meaningful and Durable Responses in Second-line Advanced Basal Cell Carcinoma
Objective responses seen in approximately 29% of patients with locally advanced basal cell carcinoma (BCC)
Regeneron and Sanofi Provide Update on U.S. Phase 2/3 Adaptive-Designed Trial of Kevzara® (sarilumab) in Hospitalized COVID-19 Patients
Independent Data Monitoring Committee recommended continuing ongoing Phase 3 trial only in the more advanced "critical" group with Kevzara higher-dose versus placebo and discontinuing less advanced "severe" group
Phase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival
Regeneron Pharmaceuticals, Inc. and Sanofi announced the primary endpoint of overall survival was met in a Phase 3 trial comparing the PD-1 inhibitor Libtayo® to platinum-doublet chemotherapy in patients with first-line locally advanced or metastatic non-small cell lung cancer that tested positive for PD-L1 in ≥50% of tumor cells.
Sanofi (NASDAQ: SNY; EURONEXT: SAN) Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8719551-sanofi-earnings-results-q1-2020/ Rapid and decisive response to COVID-19 global health crisis Sanofi showed resilience and maintained full business continuity worldwide including it
Cara Care Announces Collaboration With Consumer Healthcare Business Unit of Sanofi Germany for Digestive Health
Companies’ holistic approach to digestive health combines pharmaceuticals with health interventions via digital platform to help cope with complex conditions BERLIN--( BUSINESS WIRE )-- Digital health company HiDoc Technologies GmbH, dba Cara Care , has teamed up with the Consumer Healthcare Business Unit of Sanofi Germany on a holistic approach to digestive health that bundles Sanofi’s Buscomint ® bei Reizdarm pharmaceutical drug with Cara Care